New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
08:31 EDTMDVNMedivation price target raised to $92 from $84 at Maxim
Maxim raised its price target for Medivation shares to $92 following the company's Q4 results and keeps a Buy rating on the stock.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 17, 2015
12:53 EDTMDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
07:07 EDTMDVNMedivation to present data in TNBC at ASCO
Medivation announced that the following abstract will be presented during an oral presentation at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting on June 1, in Chicago: Results from a phase 2 study of enzalutamide, an androgen receptor, or AR, inhibitor, in advanced AR+ triple-negative breast cancer, or TNBC.
May 8, 2015
07:15 EDTMDVNMedivation price target raised to $142 from $130 at UBS
Subscribe for More Information
06:59 EDTMDVNMedivation weakness a buying opportunity, says William Blair
William Blair recommends using the post-earnings weakness in shares of Medivation as a buying opportunity. The firm believes Xtandi sales growth in prostate cancer remains strong despite the Q1 miss and raised its price target for shares to $154 from $144. It keeps an Outperform rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use